Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C30H44N2O14 |
| Molecular Weight | 656.6754 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(OCOC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N2CCC[C@@H]2C(=O)OCOC(=O)OC3CCOCC3)OC4CCOCC4
InChI
InChIKey=KSKLDMGKWDUQCT-DNQXCXABSA-N
InChI=1S/C30H44N2O14/c33-25(31-13-3-5-23(31)27(35)41-19-43-29(37)45-21-9-15-39-16-10-21)7-1-2-8-26(34)32-14-4-6-24(32)28(36)42-20-44-30(38)46-22-11-17-40-18-12-22/h21-24H,1-20H2/t23-,24-/m1/s1
RO-638695 (also known as Miridesap, CPHPC and GSK-2315698) is an antineoplastic and a serum amyloid P component inhibitor. RO-638695 almost completely depletes circulating serum amyloid P component (SAP), but a small amount of SAP is left for recognition by subsequently administered therapeutic IgG anti-SAP antibodies. SAP is a blood protein that is the target of a novel immunotherapy approach. RO-638695 has therefore been evaluated in phase I and II clinical trials for its safety and potential in treatment of diseases like Alzheimer’s disease, HIV infection and other diseases with systemic amyloid deposition.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1819986-22-5
Created by
admin on Wed Apr 02 20:31:29 GMT 2025 , Edited by admin on Wed Apr 02 20:31:29 GMT 2025
|
PRIMARY | |||
|
300000042480
Created by
admin on Wed Apr 02 20:31:29 GMT 2025 , Edited by admin on Wed Apr 02 20:31:29 GMT 2025
|
PRIMARY | |||
|
85VWJ67FZE
Created by
admin on Wed Apr 02 20:31:29 GMT 2025 , Edited by admin on Wed Apr 02 20:31:29 GMT 2025
|
PRIMARY | |||
|
92136018
Created by
admin on Wed Apr 02 20:31:29 GMT 2025 , Edited by admin on Wed Apr 02 20:31:29 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
